Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikael Sunnåker

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
BMC Systems Biology|September 9, 2011
A method for zooming of nonlinear models of biochemical systemsMikael Sunnåker, Gunnar Cedersund, Mats Jirstrand
Pharmacology Research & Perspectives|May 8, 2026
Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor MitiperstatMikael Sunnåker, Jacob Leander, Hans Ericsson
Plos Computational Biology|August 29, 2015
Efficient Characterization of Parametric Uncertainty of Complex (Bio)chemical NetworksClaudia Schillings, Mikael Sunnåker, Jörg Stelling, et al.
BMC Systems Biology|March 20, 2010
Zooming of states and parameters using a lumping approach including back-translationMikael Sunnåker, Henning Schmidt, Mats Jirstrand, et al.
Mathematical Medicine and Biology : a Journal of the IMA|October 4, 2011
Investigations of a compartmental model for leucine kinetics using non-linear mixed effects models with ordinary and stochastic differential equationsMartin Berglund, Mikael Sunnåker, Martin Adiels, et al.
BMC Bioinformatics|January 31, 2020
TopoFilter: a MATLAB package for mechanistic model identification in systems biologyMikołaj Rybiński, Simon Möller, Mikael Sunnåker, et al.
Plos Computational Biology|January 24, 2013
Approximate Bayesian computationMikael Sunnåker, Alberto Giovanni Busetto, Elina Numminen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 17, 2021
A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseasesJacob Leander, Mikael Sunnåker, Dinko Rekić, et al.
Pharmacology Research & Perspectives|March 6, 2024
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic dosesJoanna Parkinson, Jesper Sundell, Dinko Rekić, et al.
Clinical Pharmacology and Therapeutics|July 4, 2024
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH TrialsAnne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
BMC Systems Biology|September 9, 2011
A method for zooming of nonlinear models of biochemical systemsMikael Sunnåker, Gunnar Cedersund, Mats Jirstrand
Pharmacology Research & Perspectives|May 8, 2026
Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor MitiperstatMikael Sunnåker, Jacob Leander, Hans Ericsson
Plos Computational Biology|August 29, 2015
Efficient Characterization of Parametric Uncertainty of Complex (Bio)chemical NetworksClaudia Schillings, Mikael Sunnåker, Jörg Stelling, et al.
BMC Systems Biology|March 20, 2010
Zooming of states and parameters using a lumping approach including back-translationMikael Sunnåker, Henning Schmidt, Mats Jirstrand, et al.
Mathematical Medicine and Biology : a Journal of the IMA|October 4, 2011
Investigations of a compartmental model for leucine kinetics using non-linear mixed effects models with ordinary and stochastic differential equationsMartin Berglund, Mikael Sunnåker, Martin Adiels, et al.
BMC Bioinformatics|January 31, 2020
TopoFilter: a MATLAB package for mechanistic model identification in systems biologyMikołaj Rybiński, Simon Möller, Mikael Sunnåker, et al.
Plos Computational Biology|January 24, 2013
Approximate Bayesian computationMikael Sunnåker, Alberto Giovanni Busetto, Elina Numminen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 17, 2021
A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseasesJacob Leander, Mikael Sunnåker, Dinko Rekić, et al.
Pharmacology Research & Perspectives|March 6, 2024
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic dosesJoanna Parkinson, Jesper Sundell, Dinko Rekić, et al.
Clinical Pharmacology and Therapeutics|July 4, 2024
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH TrialsAnne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, et al.
Pageof 3